✓ Translated by DotMD AI Clinical Council Source: Cell reports. Medicine • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #37852180 ↗

Phase III Randomized Trial: SPOTlight on GLOW

Original Paper Title: “SPOTlight on GLOW”

Elena Rostova (AI Quant) Rigor Score
88 / 100
Sample Size (Participants)
Systematic Review
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • The GLOW randomized double-blind phase 3 trial 1 shows that Claudin-18.2 targeting antibody zolbetuximab combined with capecitabine and oxaliplatin improves outcome compared to placebo and chemotherapy as first-line treatment in Claudin-18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinomas.
  • Study Design & Sample: Phase III Randomized Trial published in Cell reports. Medicine (Multi-cohort synthesis).
  • Biostatistical Rigor Score: 88/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Cell reports. Medicine (2023), this phase iii randomized trial evaluating human clinical outcomes investigated: The GLOW randomized double-blind phase 3 trial 1 shows that Claudin-18.2 targeting antibody zolbetuximab combined with capecitabine and oxaliplatin improves outcome compared to placebo and chemotherapy as first-line treatment in Claudin-18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinomas. Key clinical takeaway: The GLOW randomized double-blind phase 3 trial 1 shows that Claudin-18.2 targeting antibody zolbetuximab combined with capecitabine and oxaliplatin improves outcome compared to placebo and chemotherapy as...

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Cell reports. Medicine, 2023-10-17; Phase III Randomized Trial; Rigor 88/100): The GLOW randomized double-blind phase 3 trial 1 shows that Claudin-18.2 targeting antibody zolbetuximab combined with capecitabine and oxaliplatin improves outcome compared to placebo and chemotherapy as first-line treatment in Claudin-18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinomas.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: capecitabine → Rx: stomach-relief-ultra-strength-bismuth-subsalicylate → Rx: stomach-relief-24-7-life-by-7-eleven-bismuth-subsalicylate-tablet → Condition: velopharyngeal-incompetence → Condition: tenderness-rebound →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 37852180: Phase III Randomized Trial: SPOTlight on GLOW

3 of 3 Free Questions Remaining